Avantor, Inc. (AVTR): what the price requires
At today's price, Avantor, Inc. (AVTR) is priced for +6.4% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.
Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/AVTR
Headline
| Field | Value |
|---|---|
| Ticker | AVTR |
| Company | Avantor, Inc. |
| Current price | $10.52/sh |
| Composition | Laboratory Solutions 67% / Bioscience Production 33% |
What The Price Requires (Inversion)
The assumption today's price embeds, recovered by inverting the valuation.
| Field | Value |
|---|---|
| Inversion basis | whole-company |
| Operating margin needed | 2.2% |
| Operating margin (mid-cycle) | 10.0% |
| Margin compression implied | -7.8pp |
| Trailing margin (depressed year) | -4.2% |
| Implied growth | 6.4% |
| Multiple paid | 17x mid-cycle operating income |
The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.
Solve inputs: computed at a 8.5% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~6.6pp.
How unusual the bet is: within-range (limited comparison data)
| Reference | Value |
|---|---|
| vs own history | -0.02σ |
| implied end-window share | 0% |
Valuation X-Ray
The price is justified by relative-multiple; earnings-power/growth-DCF land below the price.
How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.
| Family | Median price/FV | Models | Reads |
|---|---|---|---|
| Asset | 1.42x | 3 | expensive |
| Earnings | 6.08x | 3 | expensive |
| Relative | 0.43x | 2 | justifies |
| Growth | 1.67x | 3 | expensive |
Families that justify the price: Relative Families that call it expensive: Earnings, Growth
The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 6.3%); the inversion above states its own rate.
Per-Model Detail (n=11)
| Model | Family | FV | Price/FV | Applicable | Methodology |
|---|---|---|---|---|---|
| DCF Perpetual Growth | Growth | $5.00 | 2.10x | yes | FCF base $0.4B, growth -2% (input: historical growth), terminal g 0.5%, WACC 6.3%, 5yr projection |
| DCF Exit Multiple | Growth | $10.07 | 1.04x | yes | Exit EV/EBITDA: 86.1x / 88.1x / 90.1x (bear / base = today's held flat / bull), 5yr |
| Relative Valuation | Relative | $24.20 | 0.43x | yes | P/S fallback (negative EPS): Sector P/S 2.5x × TTM revenue — excluded from consensus |
| Simple DDM | Growth | — | — | no | — |
| Two-Stage DDM | Growth | — | — | no | — |
| Simple Excess Return | Asset | $8.26 | 1.27x | yes | Reference only (book value floor): BV/sh $8.26, ROE negative |
| Two-Stage Excess Return | Asset | $7.43 | 1.42x | yes | Reference only (book value with convergence): BV/sh $8.26, ROE converges to ke |
| Discounted Future Market Cap | Growth | $6.29 | 1.67x | yes | Rev $6.6B, growth -2% (input: historical growth; tapered), Terminal P/S: 0.9x / 1.1x / 1.3x (bear / base = today's held flat / bull, cap 8x) |
| Peter Lynch Fair Value | Relative | $0.00 | — | no | Negative/zero EPS — earnings-based value floored at $0 |
| Margin Trajectory | Growth | — | — | no | — |
| Earnings Power Value | Earnings | $14.05 | 0.75x | yes | Normalized EBIT (5y avg op income, one-time charges added back) $1.06B × (1−22%) / WACC 6.3% → EPV (no growth) |
| Residual Income | Asset | — | — | no | — |
| Graham Number | Asset | — | — | no | — |
| EV/EBITDA Relative | Relative | $0.01 | 1051.50x | yes | EBITDA $0.12B × sector EV/EBITDA 12.0x (excluded from median) |
| FCF Yield | Earnings | $1.73 | 6.08x | yes | FCF $438.9M / Kₑ 9.3% — zero-growth perpetuity |
| SBC-Adj FCF Yield | Earnings | $1.05 | 10.01x | yes | SBC-adj FCF $0.40B (FCF $0.44B − SBC $0.04B) capitalized at Kₑ |
| Ben Graham Formula | Earnings | — | — | no | — |
| ROIC-Justified P/B | Asset | $1.11 | 9.47x | yes | BV $8.26 × (ROIC 0.8% / WACC 6.3%) |
| P/Sales Sector | Relative | $24.20 | 0.43x | yes | Revenue $6.55B × sector P/S 2.5x |
| PEG Fair Value | Relative | — | — | no | — |
| Earnings Yield | Earnings | — | — | no | — |
| Funds From Operations Multiple | Relative | — | — | no | — |
| Clinical Phase NPV | Growth | — | — | no | — |
| Merton | Asset | — | — | no | — |
| V5 Mechanical | — | — | — | no | — |
Solvency
| Field | Value |
|---|---|
| Net debt | $3.6b |
| Net debt / NOPAT (after-tax) | 7.06x |
| Net debt / operating income (pre-tax) | 5.51x |
| Interest coverage | 3.7x |
| Share count CAGR (buyback) | -0.2% |
| Burning cash | no |
Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 10.0%); the trailing year was depressed.
Bullet Takeaways
At $9.57 the price pays about 16x mid-cycle operating income, implying roughly 4.5% operating growth a year for five years. That is a modest bar for a lab-supplies and bioscience platform, and the reverse-DCF range collapses essentially to the current price, so the market is paying about what a base-case recovery is worth.
The balance sheet is the story. Net debt of roughly $3.56 billion sits against trailing operating income that is negative once the cycle runs through, and management has put debt reduction at the top of capital allocation priorities. The price assumes a turn, and the leverage means the turn has to arrive.
The methods split. The relative multiple supports the price; earnings-power and growth-DCF frames say expensive. Q1 2026 showed early signs of stabilization, adjusted EPS of $0.17 on sales of $1,581 million, but organic sales still fell 4.1%, and new leadership is being installed to drive the transformation.
Bull Case
Start with the balance sheet, because it is both the risk and the tell on management's confidence. Avantor carries net debt of roughly $3.56 billion against $279 million of liquid assets, and the leadership has made debt reduction the explicit top priority in capital allocation. That choice signals a management team that believes the cash flow is there to deleverage rather than one reaching for growth it cannot fund. The business still generates real free cash flow, roughly $439 million on a trailing basis, which is what makes a debt-paydown plan credible rather than aspirational.
The operating turn is showing early signs. Q1 2026 net sales of $1,581 million were roughly flat year over year, with net income of $43 million and adjusted EBITDA of $219 million. CEO Emmanuel Ligner said results exceeded expectations on improved execution in Bioscience and Medtech Products and stabilization in the VWR lab-distribution business, and stated Avantor is turning a corner financially with a return to positive growth expected in the second half. Within the mix, process chemicals grew double digits, the recurring, consumable-driven part of the bioscience franchise that tends to be stickiest. The FY2025 10-K frames adjusted operating income margin as the lens for the underlying trend across periods, and that is the metric the turnaround has to move.
The valuation bar is low, which is the bull's leverage. The price implies only about 4.5% operating growth for five years on the company's own through-the-cycle margins, a pace the inversion notes is within what Avantor has recently delivered. A consumables-weighted supplier to pharma and biotech research has a more recurring revenue base than the depressed trailing numbers suggest, because the cycle, not the franchise, is what dragged margins down. New executives in Bioscience and Medtech and in Quality and Regulatory have been brought in to drive the transformation. If execution stabilizes lab demand and the second-half growth inflection lands, a deleveraging, cash-generative platform priced for almost no growth has room to re-rate.
Bear Case
The variable with the most leverage on this thesis is end-market demand for laboratory research, and it is the one Avantor controls least. Its customers are pharma, biotech, academic, and government labs, and their spending swings with research funding, biotech financing conditions, and policy. Q1 2026 organic sales still fell 4.1%, with Laboratory Solutions down 5% organically, even as management called a corner turned. A platform this exposed to research budgets does not set its own demand, and the current price assumes that demand stabilizes and turns positive in the second half on a timeline management has guided but not yet proven.
The balance sheet turns that macro sensitivity into real risk. Net debt of roughly $3.56 billion against trailing operating income that is negative once the cycle runs through leaves little room if the recovery slips. The asset and earnings frames say the equity is not cheap on current economics: residual income screens as negative because ROE is around negative 10% against a 9.3% cost of equity, the ROIC-justified book mark lands near $1, and the zero-growth FCF-yield mark sits near $1.70. Earnings power value at about $14.62 is one of the few marks above the price, and it depends on normalized rather than trailing margins. Strip out the normalization and the trailing picture is a levered business with negative operating income.
The transformation itself is the uncertainty. Avantor is installing new leadership, a Chief Transformation Officer in Bioscience and Medtech and a new Quality and Regulatory head, which is what a company does when execution has been the problem. Management embedded inflationary headwinds into guidance and reaffirmed rather than raised, a posture of caution. The relative multiple is the only frame that comfortably reaches the price, and it does so on a sector price-to-sales assumption, not on the company's own profitability. The bet is that a leadership change stabilizes demand it does not control, that the second-half inflection arrives on schedule, and that free cash flow deleverages the balance sheet before a slower-for-longer research environment tests it. Each link has to hold.
Valuation
Inverting the $9.57 price (June 27, 2026) gives the anchor. At that level the market pays about 16x company-wide mid-cycle operating income, which under an 8.5% cost of capital and 4% terminal growth implies operating growth of roughly 4.5% a year for five years. Because trailing earnings are depressed by the cycle, the solve uses Avantor's own through-the-cycle margins on current revenue rather than the trough quarter. The inversion notes that near-term pace is within what the company has recently delivered, so the priced-in assumption reads as within range, though with limited comparison data the label is directional. The reverse-DCF range is tight, essentially clustering at the current price.
The model X-ray splits by family. The relative multiple supports the price: a sector price-to-sales mark near $24 on 2.5x revenue, which is what carries the within-range read. The earnings-power and growth frames say expensive: a perpetual-growth DCF near $5.33 on negative historical growth, a discounted future market cap near $5.72, and the zero-growth FCF-yield mark near $1.73. The asset frames are reference-only book-value floors near $7.43 to $8.26 because ROE is negative. Earnings power value at $14.62, built on five-year normalized EBIT, is the optimistic mark and the clearest expression of the recovery case.
The spread is the information. The price is not a verdict on whether Avantor is a good lab-supplies franchise. It is a measure of how much recovery the market has booked: a return to roughly mid-single-digit growth and through-the-cycle margins, on a balance sheet that has to deleverage from about $3.56 billion of net debt while it gets there.
Catalysts
The near-term driver is the second-half growth inflection management has guided. Q1 2026 delivered $1,581 million in sales, roughly flat year over year, with adjusted EPS of $0.17 and adjusted EBITDA of $219 million, and CEO Emmanuel Ligner said Avantor is turning a corner with a return to positive growth expected in the second half. Whether organic sales, down 4.1% in Q1 with Laboratory Solutions off 5%, actually inflect positive is the swing factor for the year and the multiple.
The transformation and leadership changes are the structural catalyst. Avantor appointed Ludovic Brellier as EVP of Bioscience and Medtech Products and Chief Transformation Officer, and Gerard Porreca as EVP of Quality and Regulatory. Execution under the new team, particularly stabilizing Laboratory Solutions and sustaining double-digit growth in process chemicals, is what the recovery case rests on.
Debt reduction is the capital-allocation catalyst. Management placed deleveraging at the top of priorities against net debt near $3.56 billion. Watch organic growth by segment, adjusted EBITDA margin trajectory, free-cash-flow conversion, and progress on debt paydown, plus the research-funding and biotech-financing backdrop that drives lab demand.
Sources: Avantor Q1 2026 earnings release and AOL/Motley Fool transcripts (Q1 2026 results, $0.17 adjusted EPS, segment organic declines, second-half growth guidance), Yahoo Finance (margins decline, beat on revenue and EPS), Simply Wall St (transformation-focused leadership appointments).
Peer Cohorts (Per Segment, With Filing Citations)
Laboratory Solutions (reported)
- TMO (THERMO FISHER SCIENTIFIC INC.)
- (no filing in the citation store)
- DHR (Danaher Corporation)
- (no filing in the citation store)
- A (AGILENT TECHNOLOGIES, INC.)
- (no filing in the citation store)
- MTD (Mettler-Toledo International Inc.)
- (no filing in the citation store)
- BRKR (BRUKER CORPORATION)
- (no filing in the citation store)
- RVTY (REVVITY, INC)
- (no filing in the citation store)
- WAT (Waters Corporation)
- (no filing in the citation store)
Bioscience Production (reported)
- RGEN (REPLIGEN CORP)
- (no filing in the citation store)
- DHR (Danaher Corporation)
- (no filing in the citation store)
- TMO (THERMO FISHER SCIENTIFIC INC.)
- (no filing in the citation store)
- WST (WEST PHARMACEUTICAL SERVICES, INC.)
- (no filing in the citation store)
- RVTY (REVVITY, INC)
- (no filing in the citation store)
- BRKR (BRUKER CORPORATION)
- (no filing in the citation store)
Methodology Note
- Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
- Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
- Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
- Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.
Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.